# Stuck on your GLP-1? What a stall is, what it isn’t, and what to ask your provider > A Wegovy stall is often four weeks of no change on the scale. Here is what that usually means and what is worth asking a provider. Source: https://livingplusrx.com/wegovy-stall-what-to-ask/ Publisher: Living+ Rx (livingplusrx.com) Author: Living+ Published: 2026-05-28 Last updated: 2026-11-07 A stall usually means about a month with no real change on the scale. It is a reason to ask about dose, tracking and blood work, and it does not prove the drug failed. A single noisy week can be water, salt, a period or a hard workout. In the STEP 1 obesity trial of semaglutide 2.4 mg, 86.4 percent lost at least 5 percent of their weight by week 68, so some people did not reach that mark. Public reviews of the big GLP-1 subscription programs pile up around bills that did not match the ad, and around boxes that never showed. Chats that never produced a person sit in the same pile. A smaller share say the medicine did not change anything they could feel. Angry people post. Satisfied people mostly do not. The sample is still a bind you can recognize: you keep paying, the number does not move, and there is no one to ask. Loss often slows as the body gets smaller. Fat and some muscle both come off, and a lighter body burns fewer calories than the heavier one did, even on the same meals. NIH modelers have shown why the old fridge-magnet rule fails here. Cut a fixed number of calories and the burn falls as weight falls, so the deficit you started with can shrink without a secret snack. Some researchers talk about a set point the brain tries to defend, with hunger hormones rising as fat stores fall. Resting burn can drop more than the lost tissue would predict, a pattern clinicians call metabolic adaptation. The scale can go quiet while the shot is still blunting appetite, which is infuriating if you were promised a straight line down. That quiet stretch shows up in the drug trials too. Weight fell fastest early, then leveled. A plateau after real loss belongs in a different conversation from never getting started. In the main FDA study of Wegovy in people with obesity, 86.4 percent lost at least 5 percent of their weight by week 68. The rest did not hit that mark. Some people are non-responders. A stall after months of movement does not automatically put you in that group. Sorting those two is clinical work. Tirzepatide trials show the same spread. In SURMOUNT-1, 85 to 91 percent of people on the drug lost at least 5 percent by week 72, depending on the dose. A Zepbound plateau after real loss is still a plateau, and it does not prove the month was a lie. ## What a Wegovy stall looks like on a calendar Starter doses are not the dose the label aims for. The FDA schedule for Wegovy steps up every four weeks unless a clinician holds you for side effects. Nausea is common on the way up. Holding a dose is a medical choice, and guessing your way past it is how people get sick. Daily swings also fail the four-week test. A waist tape, shot dates, and an honest log of what you ate are fair data. So is the week of takeout you did not write down. ## What to ask in the room Forums fill up with homework. Treat those threads as a prompt list for a visit, not a protocol you run on yourself. Ask what dose you are on, and whether a change is even being considered. Ask how they want weight tracked so a bad Wednesday does not get counted as a month. Ask whether strength work belongs in this phase. Federal activity guidelines treat muscle-building work as part of weekly movement for adults. Bring it as a question. Ask if blood work is due. NIDDK names thyroid disease, some mood medicines, steroids, and short sleep among things that can move weight. A stall is a reason to look. You do not diagnose that from a comment thread. Ask whether another medicine is even on the table. Combining drugs is a medical decision with risks, and copying a stranger’s stack is a bad way to find out what those risks are. This page cannot pick among those options. A program that never puts a person on the line leaves you to pick anyway, which is how people get hurt. At Living+ compounded semaglutide is 197 dollars a month and tirzepatide is 247, flat. Each month includes a personal coach. There is no separate visit fee. The price does not rise with the dose. If a clinician declines you, you are not charged. Compounded copies are not FDA-approved Wegovy or Zepbound. A stall on any GLP-1 still belongs in a visit. Bring how long the number has been flat, and what you want checked. Leave the shame. Prices were accurate at the time this was published. **Related on Living+:** [Semaglutide vs tirzepatide](https://livingplusrx.com/semaglutide-vs-tirzepatide/) · [Semaglutide](https://livingplusrx.com/semaglutide/) · [Tirzepatide](https://livingplusrx.com/tirzepatide/) · [GLP-1 weight loss with Living+](https://livingplusrx.com/weight-loss/) ## Common questions ### How long does a GLP-1 plateau have to last to count? About a month with no loss is a common line. A Houston Methodist doctor describes a plateau as going a month without losing anything, so one bad week does not qualify. ### Does a stall mean I am a non-responder? Not automatically. A stall after months of real loss is a different question from never reaching 5 percent. ### Should I raise my dose myself during a stall? No. Wegovy steps up every four weeks unless a clinician holds you for side effects, and holding a dose is a medical choice. Ask your provider whether a change is even being considered. ### What should I ask my provider about a Wegovy stall? Ask what dose you are on, how they want weight tracked, and whether blood work is due. NIDDK names thyroid disease, some mood medicines, steroids and short sleep among things that can move weight. ## Sources - [FDA: Wegovy (semaglutide) prescribing information, 2021](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf) - [Wilding et al.: Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1), PubMed](https://pubmed.ncbi.nlm.nih.gov/33567185/) - [Jastreboff et al.: Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), PubMed](https://pubmed.ncbi.nlm.nih.gov/35658024/) - [Hall et al.: Quantification of the effect of energy imbalance on bodyweight, PMC](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3880593/) - [StatPearls: Management of Weight Loss Plateau](https://www.ncbi.nlm.nih.gov/books/NBK576400/) - [StatPearls: Metabolic Consequences of Weight Reduction](https://www.ncbi.nlm.nih.gov/books/NBK572145/) - [NIDDK: Factors Affecting Weight and Health](https://www.niddk.nih.gov/health-information/weight-management/adult-overweight-obesity/factors-affecting-weight-health) - [Houston Methodist: Not Losing Weight on a GLP-1? Here's What Could Be Happening](https://www.houstonmethodist.org/blog/articles/2026/jun/not-losing-weight-on-a-glp-1-here-s-what-could-be-happening/) - [HHS: Physical Activity Guidelines for Americans](https://health.gov/our-work/nutrition-physical-activity/physical-activity-guidelines/current-guidelines) - [FDA: Compounding and the FDA — Questions and Answers](https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers) See what a Living+ plan costs and whether it fits. [**See treatments and pricing**](https://livingplusrx.com/weight-loss/) Wegovy is a registered trademark of Novo Nordisk A/S. Zepbound is a registered trademark of Eli Lilly and Company. Living+ is not affiliated with or endorsed by these companies.